Influence of Bailing capsule on the serum levels of hs-CRP, IL-18, TNF-α in patients with chronic kidney disease / 中国基层医药

ABSTRACT

Objective To observe the influence of Bailing capsule on the serum levels of hs-CRP,IL-18,TNF-α in patients with chronic kidney disease (CKD).Methods According to the digital table,56 CKD patients were randomly divided into the control group(28 cases) and treatment group(treated with Bailing capsules,28 cases).Meanwhile,20 healthy adults were selected as the normal controls.The blood concentrations of hs-CRP,IL-18,TNF -α,Scr and BUN were determined.Results The levels of hs-CRP,IL-18,TNF-α,Scr and BUN in CKD patients were significantly higher than those in the normal control [(5.99 ± 2.67) mg/L,(6.17-± 2.23) mg/L vs.(2.27 ± 2.16) mg/L,(44.43 ± 7.54)μg/L,(46.54 ± 8.63)μg/L vs.(11.42 ± 3.32) μg/L,(95.22 ± 34.65) ng/L,(105.48 ± 33.25) ng/L vs.(21.34-± 10.10) ng/L,(6.86 ± 2.97) mmol/L,(6.89 ± 2.85) mmol/L vs.(5.32 ±2.43) mmol/L,(98.47 ± 28.85) μmol/L,(95.46 ± 27.83) μmol/L vs.(75.45 ± 28.20)μmol/L,all P ＜ 0.05].The levels of hs-CRP,IL-18,TNF-α,Scr and BUN decreased after 12 weeks of conventional treatment (t =-0.22,-1.30,-1.76,-0.67,-1.16,all P ＞0.05),while those were significantly decreased with Bailing capsule treatment (t =-2.77,-3.81,-4.71,-2.06,all P ＜ 0.05).Conclusion The renal inflammation can be alleviated by Bailing capsule in CKD patients,which can slow the progression of CKD.